Fundraising Fox
XOMA
acquired by LigandFounded 1981 · 131 employees on LinkedIn · 3 known investors
Find your way into XOMA
Sign up to see every warm intro you have to XOMA
- Paths you didn't know you had: your email and LinkedIn already hold routes to the XOMA team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Ligand Pharmaceuticals July 2026 · $739M ($39.00 per share in cash, total equity value ~$739 million) · source ↗
XOMA Royalty is a biotech royalty aggregator that acquires the economic rights to future milestone and royalty payments tied to partnered pre-commercial clinical candidates, providing sellers with non-dilutive, non-recourse funding. It serves biotech companies seeking capital to advance their internal drug candidates, holding a portfolio of 120+ assets.
Founders & leadership
BS
Brad SitkoChief Investment OfficerHe brings experience in corporate finance, M&A, capital raising, and biotech investing, with expertise in royalty monetization and structured finance.
MM
Maricel MontanoChief Legal Officer
Investors · 3
Related companies · 2
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as XOMA.
Frequently asked questions
- What does XOMA do?
- XOMA Royalty is a biotech royalty aggregator that acquires the economic rights to future milestone and royalty payments tied to partnered pre-commercial clinical candidates, providing sellers with non-dilutive, non-recourse funding. It serves biotech companies seeking capital to advance their internal drug candidates, holding a portfolio of 120+ assets.
- Who are XOMA's investors?
- XOMA's investors include HEALTHCARE ROYALTY PARTNERS, Ligand Pharmaceuticals, Sanderling Ventures.
- Who acquired XOMA?
- XOMA was acquired by Ligand.